Skip to content

COVID-19 Infection and Idiopathic Membranous Nephropathy

The Association of COVID-19 Infection and Relapse of Idiopathic Membranous Nephropathy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05691179
Enrollment
130
Registered
2023-01-19
Start date
2022-12-10
Completion date
2023-05-31
Last updated
2023-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Membranous Nephropathy

Brief summary

Infection is one of common risk factors for relapsing of idiopathic membranous nephropathy (IMN). However, it is still unclear wheather COVID-19 infection can induce the relapsing of IMN. Herein, in this prospective, multi-center, cohort study, the investigator enrolled the IMN patients with COVID-19 infection. All subjects will be followed for three months with four visits at 1, 2 and 3 months. Then the investigator will compare the rate of replase of IMN in the two groups to evaluate the association of COVID-19 infection and replapse of IMN.

Interventions

None listed

Sponsors

Beijing Pinggu District Hospital
CollaboratorOTHER
Beijing Fangshan District Liangxiang Hospital
CollaboratorOTHER
Beijing Friendship Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. the status of nephrotic syndrome is complete remmision or partial remmision; 2. estimated glomerular filtration rate (eGFR according to the CKD-EPI formula) ≥60 mL/min per 1.73 m2; 3. patients with a moderate risk of IMN.

Exclusion criteria

1. secondary causes of MN; 2. the labarotary data two months before enrolement is absent.

Design outcomes

Primary

MeasureTime frameDescription
primary outcome3 monthsrelaspe of nephrotic syndrome: proteinuria\<0.3g/d, serum albumin\>30g/l, serum creatitine below 111 μmol/l

Secondary

MeasureTime frameDescription
secondary outcome0.5, 1, and 2 monthsrelaspe of nephrotic syndrome: proteinuria\<3.5g/d (decreased over 50% of baseline), serum albumin\>30g/l, steady serum creatitine (fluctuated less than 20% of baseline), meet the above criteria over 2 times

Countries

China

Contacts

Primary ContactZongli Diao, Dr.
diaozl@ccmu.edu.cn86-10-63138579

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026